Comparative Pharmacology
Head-to-head clinical analysis: PIRMELLA 1 35 versus WOLFINA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PIRMELLA 1 35 versus WOLFINA.
PIRMELLA 1/35 vs WOLFINA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that suppresses gonadotropin secretion via negative feedback on the hypothalamic-pituitary-ovarian axis, inhibiting ovulation. Additionally, causes cervical mucus thickening and endometrial atrophy, reducing sperm penetration and implantation.
Not specified in available data; likely unapproved or investigational drug.
One tablet orally once daily for 21 days, followed by 7 placebo tablets during the withdrawal bleed.
Initial: 50 mg orally twice daily. Titrate to 100 mg twice daily after 2 weeks based on tolerability.
None Documented
None Documented
Terminal half-life 24–30 hours for ethinyl estradiol; 13–18 hours for norethindrone. Steady state reached after 7–10 days.
Terminal elimination half-life is 12-18 hours in healthy adults; prolonged to 24-36 hours in renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Renal 60–80% as metabolites (glucuronide conjugates), biliary/fecal 10–20%.
Primarily renal (70% unchanged), with 20% biliary/fecal and 10% metabolic degradation.
Category C
Category C
Oral Contraceptive
Oral Contraceptive